Mink Therapeutics Inc (INKT NASDAQ) stock market data APIs
$0.78
-0.07(-8.2%)
as of January 14, 2025
Mink Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Prev. Close
0.85
Open
0.78
Volume
123 K
High
0.86
Low
0.737
52 wk Range
0.4632-1.9
Market Cap
30 670 K
Shares Outstanding
39 630 K
Revenue
0
EPS
-0.05
Beta
0.048
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mink Therapeutics Inc data using free add-ons & libraries
Get Mink Therapeutics Inc Fundamental Data
Mink Therapeutics Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -17 249 290
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-14
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mink Therapeutics Inc News
New
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797 demonstr...
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 mont...
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of alloge...
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of alloge...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
